Phosphagenics soars on Phase I oxymorphone patch results
This article was originally published in Scrip
Executive Summary
It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.